The American Society of Clinical Oncology has released new resources to help healthcare providers and patients manage the complications of obesity in patients with cancer, the organization announced.
The American Society of Clinical Oncology has released new resources to help healthcare providers and patients manage the complications of obesity in patients with cancer, the organization announced.
The patient guide, "Managing Your Weight After a Cancer Diagnosis," and the healthcare practitioner guide, "Obesity and Cancer: A Guide for Oncology Providers," are designed to help manage the complications of obesity in patients with cancer and facilitate communication about the importance of weight management and making healthy lifestyle choices following a cancer diagnosis.
In a similar vein, the Oncology Nursing Society (ONS) recently introduced its “Get Up, Get Moving,” campaign at the organization’s annual meeting held May 1-4, the goal of which is to increase the number of patients who receive safe and effective recommendations from their nurses to participate in physical activity.
"Obesity is a defining public health challenge for our nation today," ASCO President Clifford A. Hudis, MD, FACP, said in a statement "As oncologists, we have an obligation to take on this challenge, providing ways to reduce the risk of obesity-related cancers, and equipping physicians and patients with the education and tools they need to ensure everyone receives the best possible cancer care."
Obesity has been linked with an increased risk for many of the most common cancers, including breast, colon, and high-grade prostate cancers and has been linked to poorer outcomes among patients diagnosed with cancer, including higher risk of side effects, cancer recurrence, and mortality.
The new guides feature a range of tools and information, such as recommendations for providers to help them assist overweight and obese cancer survivors to access resources and services to lose weight and become more active, details on obesity-related services available through the Affordable Care Act, and tools to help clinicians and patients communicate effectively about common challenges patients face.
The provider guide and other resources are now available on ASCO's website, at www.asco.org/obesity
Belantamab Mafodotin Combo Yields Improved OS in Relapsed/Refractory Multiple Myeloma
December 12th 2024Updated data from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib/dexamethasone as a potential new standard of care in relapsed or refractory multiple myeloma, according to Vania Hungria, MD, PhD.
Imlunestrant +/- Abemaciclib Improves PFS in ER+/HER2– Advanced Breast Cancer Subgroup
December 11th 2024Imlunestrant, alone or in combination, may provide an all-oral, targeted therapy option following progression for patients with ESR1-mutant, ER-positive, HER2-negative advanced breast cancer.
Belantamab Mafodotin Combo Yields Improved OS in Relapsed/Refractory Multiple Myeloma
December 12th 2024Updated data from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib/dexamethasone as a potential new standard of care in relapsed or refractory multiple myeloma, according to Vania Hungria, MD, PhD.
Imlunestrant +/- Abemaciclib Improves PFS in ER+/HER2– Advanced Breast Cancer Subgroup
December 11th 2024Imlunestrant, alone or in combination, may provide an all-oral, targeted therapy option following progression for patients with ESR1-mutant, ER-positive, HER2-negative advanced breast cancer.
2 Commerce Drive
Cranbury, NJ 08512